ReviewCurrent oncology reports2026
Frailty and Quality of Life in Older Patients Treated with Chemotherapy.
Review in Current oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewOlder patients can be at higher risk of toxicity with chemotherapy due to frailty, which can have significant impacts on quality of life. Older adults have been historically underrepresented in clinical trials, making it difficult to generalize safety data for chemotherapy regimens in those with geriatric risk factors. This review aims to highlight the influence of frailty on chemotherapy tolerance and quality of life in older adults with cancer, and discusses the utilization of geriatric assessment to guide treatment decision-making and mitigate treatment related toxicity. RECENT
findingsGeriatric assessment (GA) reliably identifies frailty and other geriatric risk factors that predispose patients to chemotherapy toxicity, functional decline, and diminished quality of life. Utilizing GA regularly in practice can mitigate these risks by impacting treatment choices or proactively addressing vulnerabilities in an older patient. Care of older adults should involve a multidisciplinary team to identify deficits and successfully implement interventions. Tailoring therapy based on deficits identified during geriatric assessment can reduce risks associated with chemotherapy and promote independence and quality of life in patients. Future research should focus on safe and effective therapeutic strategies in frail older adults.
Indexed as
Identifiers
41706253What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.